The global CT and MRI contrast agents market size is anticipated to reach USD 9.77 billion by 2030 and is expected to expand at a CAGR of 7.81% during the forecast period, according to a new report by Grand View Research, Inc. The rising prevalence of chronic diseases such as cardiovascular, neurological, and oncological disorders is fueling the projected growth of the market. These conditions often require advanced imaging for accurate diagnosis and treatment planning, and contrast agents play a vital role in enhancing the clarity and precision of such scans. As healthcare systems worldwide prioritize early detection and preventive care, the demand for high-quality diagnostic imaging continues to surge, thereby driving the uptake of contrast-enhanced CT and MRI procedures.
Government initiatives aimed at expanding diagnostic infrastructure also contribute significantly to market expansion. For instance, large-scale investments in community diagnostic centers and imaging facilities have increased access to CT and MRI technologies, particularly in underserved regions. These efforts are improving healthcare delivery and creating a robust platform for the widespread adoption of contrast agents. Additionally, technological advancements in contrast media—such as the development of safer, more effective iodinated and gadolinium-based formulations—enhance patient outcomes and reduce adverse reactions, further encouraging their use in clinical settings.
The growing geriatric population, which is more susceptible to chronic illnesses requiring frequent imaging, adds another layer of momentum to the market. Moreover, the shift toward outpatient and ambulatory care settings has increased routine imaging procedures, increasing the demand for single-dose, patient-specific contrast solutions. As manufacturers continue to innovate and streamline production to meet evolving clinical needs, the CT and MRI contrast agents market is poised for sustained and dynamic growth through the forecast period.
Download a free sample PDF of the CT and MRI Contrast Agents Market Intelligence Study, published by Grand View Research.
Further key findings from the report suggest:
- By modality, the x-ray/ computed tomography segment accounted for the largest revenue share in 2024.
- By product, the iodinated contrast agents segment dominated the CT and MRI contrast agents industry in 2024.
- By application, the neurological disorders segment accounted for the largest revenue share in 2024.
- By route of administration, the intravenous segment led the market with a revenue share in 2024.
- By end use, the hospital segment accounted for the largest market share at 58.98% in 2024.
- North America dominated the global market revenue for CT and MRI contrast agents in 2024.
- The Asia Pacific CT and MRI contrast agents industry is expected to experience the fastest growth from 2025 to 2030.
- In January 2025, Bayer reported positive results from the pivotal Phase III QUANTI studies, which evaluated the efficacy and safety of gadoquatrane, an investigational GBCA intended for MRI.
List of Key Players in the CT And MRI Contrast Agents Market
- Bracco Diagnostics Inc.
- Guerbet
- GE HealthCare
- Bayer
- Fresenius Kabi USA, LLC
Explore Horizon Databook – the world’s most comprehensive market intelligence platform by Grand View Research.
No comments:
Post a Comment